Current Value
$304.331 Year Return
Current Value
$304.331 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CXSE | 48.77% | $468.26M | 0.32% |
FXI | 46.69% | $6.58B | 0.74% |
MCHI | 46.50% | $7.22B | 0.59% |
FLCH | 46.40% | $215.10M | 0.19% |
GXC | 46.33% | $464.36M | 0.59% |
EWH | 46.11% | $679.91M | 0.5% |
KLIP | 45.83% | $99.01M | 0.93% |
PGJ | 45.77% | $145.38M | 0.67% |
CHIQ | 45.57% | $244.42M | 0.65% |
KWEB | 45.23% | $7.76B | 0.7% |
CQQQ | 44.63% | $1.26B | 0.65% |
VWO | 42.16% | $95.20B | 0.07% |
FEM | 42.03% | $434.81M | 0.8% |
SPEM | 41.51% | $12.83B | 0.07% |
SCHE | 41.40% | $10.65B | 0.07% |
EMQQ | 41.18% | $371.59M | 0.86% |
AAXJ | 41.15% | $2.84B | 0.72% |
EMXF | 41.01% | $108.85M | 0.17% |
PXH | 40.80% | $1.55B | 0.47% |
EWX | 40.34% | $728.75M | 0.65% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -22.04% | $86.59M | 0.59% |
VIXY | -20.42% | $266.70M | 0.85% |
USDU | -16.95% | $136.52M | 0.5% |
VIXM | -15.50% | $25.42M | 0.85% |
XHLF | -14.54% | $1.76B | 0.03% |
UUP | -13.50% | $207.49M | 0.77% |
XBIL | -11.29% | $805.60M | 0.15% |
FTSD | -9.36% | $233.51M | 0.25% |
CLIP | -9.27% | $1.51B | 0.07% |
KCCA | -7.78% | $108.66M | 0.87% |
TBLL | -7.55% | $2.14B | 0.08% |
BIL | -7.36% | $41.72B | 0.1356% |
BILZ | -7.03% | $897.95M | 0.14% |
ULST | -6.14% | $571.27M | 0.2% |
GBIL | -6.10% | $6.40B | 0.12% |
XONE | -5.45% | $631.86M | 0.03% |
TBIL | -5.33% | $5.79B | 0.15% |
TFLO | -4.46% | $6.73B | 0.15% |
BTAL | -3.76% | $317.59M | 1.43% |
BILS | -3.32% | $3.82B | 0.1356% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SPTS | 0.23% | $5.81B | 0.03% |
KMLM | 0.32% | $190.04M | 0.9% |
CANE | -0.35% | $14.03M | 0.29% |
SGOV | -0.62% | $52.02B | 0.09% |
AGGH | 0.65% | $322.01M | 0.29% |
CORN | 0.70% | $44.41M | 0.2% |
SCHO | 0.80% | $10.94B | 0.03% |
SHYM | 1.04% | $363.57M | 0.35% |
USFR | 1.14% | $18.88B | 0.15% |
WEAT | 1.17% | $121.03M | 0.28% |
PSQA | 1.20% | $38.62M | 0.2% |
SPSK | 1.38% | $333.11M | 0.5% |
FMF | 1.49% | $165.30M | 0.95% |
UTWO | 1.64% | $373.44M | 0.15% |
BOXX | 1.66% | $7.14B | 0.19% |
BSCQ | 1.71% | $4.23B | 0.1% |
IBTH | 1.77% | $1.66B | 0.07% |
UNG | -1.83% | $408.65M | 1.06% |
TESL | -1.84% | $30.39M | 1.2% |
SHV | -2.24% | $20.84B | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SNAP | -<0.01% | $16.19B | -27.42% | 0.00% |
FISI | 0.01% | $532.10M | +6.22% | 4.58% |
WBA | 0.03% | $10.07B | -2.60% | 4.30% |
MZTI | -0.03% | $5.00B | -2.63% | 2.06% |
OMI | 0.03% | $602.95M | -49.03% | 0.00% |
PEGA | 0.03% | $10.26B | +81.86% | 0.20% |
CHCO | -0.03% | $1.83B | +5.30% | 2.47% |
ORN | -0.05% | $376.95M | +12.51% | 0.00% |
VUZI | 0.05% | $168.50M | +76.80% | 0.00% |
HUSA | 0.05% | $20.25M | -15.12% | 0.00% |
RTO | -0.06% | $12.10B | -20.84% | 2.56% |
KSS | 0.07% | $1.44B | -39.19% | 9.87% |
SBDS | 0.09% | $25.46M | -82.30% | 0.00% |
CNMD | -0.11% | $1.55B | -28.62% | 1.61% |
LION | 0.12% | $1.89B | -12.49% | 0.00% |
HURN | 0.14% | $2.31B | +17.96% | 0.00% |
SHLS | -0.14% | $974.63M | -11.40% | 0.00% |
FLUX | -0.16% | $30.27M | -50.28% | 0.00% |
GIII | 0.16% | $1.05B | -9.78% | 0.00% |
PARAA | 0.16% | $15.64B | +4.98% | 0.87% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FUTU | 42.11% | $18.34B | +171.62% | 0.00% |
XPEV | 39.60% | $14.73B | +129.85% | 0.00% |
BABA | 39.43% | $273.09B | +56.60% | 0.86% |
QFIN | 39.24% | $4.53B | +76.35% | 3.63% |
ATHM | 38.36% | $3.32B | +14.29% | 0.00% |
JD | 38.26% | $44.90B | +24.84% | 3.02% |
WB | 37.69% | $1.59B | +32.38% | 8.02% |
NOAH | 37.05% | $836.31M | +70.83% | 4.66% |
LI | 36.72% | $24.38B | +51.32% | 0.00% |
DD | 35.50% | $31.41B | -7.23% | 2.11% |
AZN | 35.37% | $222.77B | -8.33% | 2.13% |
BIDU | 34.99% | $25.02B | -1.22% | 0.00% |
HUYA | 34.94% | $266.17M | +79.21% | 0.00% |
NIO | 34.72% | $9.38B | +10.02% | 0.00% |
NTES | 34.22% | $83.85B | +44.64% | 2.10% |
BILI | 33.78% | $7.47B | +50.93% | 0.00% |
XNET | 33.12% | $317.47M | +199.41% | 0.00% |
LYG | 33.08% | $62.75B | +35.48% | 3.94% |
IQ | 32.74% | $1.02B | -40.25% | 0.00% |
ALB | 32.50% | $8.80B | -18.44% | 2.22% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DFDV | -15.39% | $264.60M | +2,316.35% | 0.00% |
STRA | -14.02% | $1.91B | -33.61% | 3.03% |
CARS | -12.78% | $842.68M | -32.56% | 0.00% |
CCRN | -12.29% | $452.74M | -16.76% | 0.00% |
NTGR | -9.13% | $734.56M | +60.30% | 0.00% |
SHEN | -8.63% | $825.60M | -26.66% | 0.66% |
BTCT | -8.31% | $27.98M | +50.77% | 0.00% |
GME | -8.24% | $10.28B | -2.63% | 0.00% |
APEI | -6.92% | $512.33M | +45.19% | 0.00% |
NGVC | -5.91% | $863.62M | +49.74% | 1.22% |
GPI | -5.90% | $5.51B | +25.65% | 0.45% |
LESL | -5.36% | $119.51M | -77.87% | 0.00% |
NRDS | -5.30% | $814.42M | -31.52% | 0.00% |
PEN | -5.28% | $8.91B | +29.03% | 0.00% |
CBZ | -5.20% | $4.17B | -9.35% | 0.00% |
AMTX | -5.09% | $180.50M | -3.83% | 0.00% |
OSW | -4.80% | $2.30B | +35.28% | 0.71% |
PRA | -4.79% | $1.22B | +103.59% | 0.00% |
EGAN | -4.72% | $177.23M | -10.12% | 0.00% |
PINC | -4.66% | $1.74B | +1.29% | 3.96% |
Yahoo
SAN CARLOS, Calif., July 10, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasophar
Yahoo
By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said it designated Veet Misra, Ph.D., as Chief Financial Officer, and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Dr. Misra has more than 20 years of experience in investment banking as well as a strong scientific background in biology, and he […]
SeekingAlpha
June welcomed 48 new Seeking Alpha analysts with bold stock ideas and diverse insights across sectors.
SeekingAlpha
Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments. Click for why I am bullish on JAZZ.
Yahoo
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 approval for Sonrotoclax and 2027 approval for BGB16673, notes the analyst, who contends that Street estimates for BGB-16673 and Sonrotoclax are “too conservative.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne
Yahoo
SAN CARLOS, Calif., June 26, 2025--In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today’s investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition.